WHO Hepatitis B Booster Policy

Milan; November 2011
Dr. Steven Wiersma
WHO Vaccine Position Paper

- primarily large-scale immunization programme issues
- individual protection not emphasized
- summarize essential background information
- conclude with WHO position concerning use in global context
- reviewed by experts inside and outside WHO
- designed for use mainly by national public health officials and immunization programme managers
- published in Weekly Epidemiological Record and on website
WHO vaccine position papers

- Process started in 1998
- Each vaccine preventable disease
- Key reference documents
  - Available in all official languages
  - Convergence of all WHO policy for a specific vaccine
- On-line catalogue: www.who.int/immunization/documents/en

Hepatitis A
- Position paper (February 2000) Original English and French versions
  - pdf, 193kb
- References
  - pdf, 31kb

Hepatitis B
- Position paper (October 2009) Original English and French versions
  - pdf, 330kb
- Grading of scientific evidence (24 hour)
  - pdf, 35kb
- Grading of scientific evidence (7 days)
  - pdf, 70kb
- Grading of scientific evidence (duration)
  - pdf, 50kb
- Grading of scientific evidence (HBIG)
  - pdf, 57kb
- Summary of WHO position paper on hepatitis B
  - pdf, 74kb
- Key references to the hepatitis B position paper
  - pdf, 177kb
- Key references, with summaries, to the hepatitis B position paper
  - pdf, 283kb
- Presentation: Summary of key points - WHO position paper on hepatitis B vaccine
  - pdf, 895kb

This version updates and replaces the previous position paper published in July 2004.
Pathways for WHO Recommendations on Vaccine Use

Industry and other partners
- Global Advisory Committee on Vaccine Safety
- Expert committee on Biological Standardization
- Technology & Logistics Advisory Committee
- Other specific or cross-cutting technical advisory committee

Input
- Request for review of evidence

Background Paper
- Relevant existing technical advisory committee
- SAGE working group
- Secretariat

SAGE

Recommendations
- WHO DG
- WHO Position Paper
- Regional TAGS
- Regional consultations
- Country Decision making

Other relevant non immunization related WHO policy recommendation making body

WHO DG

World Health Organization
PP Development and Updating Process

- Developmental and review process
  - Editorial Board staffed by consultant and IVB staff
  - Literature review, background paper, immunological basis of immunization modules
  - Draft circulated to global experts, regions, interested parties, industry, SAGE working group, SAGE members
  - Revised draft to SAGE members and others on as needed basis
  - Key recommendations agreed by SAGE. Plenary discussion before or after draft paper

- Process compliant with WHO "Guidelines for Guidelines" and WHO Guideline Review Committee
WHO Guidelines for Guidelines

- For principle and/or controversial recommendations:
  - Synthesis of all available evidence
  - Evidence summaries using standard template
  - Formal assessment of quality of evidence
  - Consideration of resource use and costs
  - Linked evidence to recommendations, explaining reasons for judgements

- System for assessing evidence for interventions:
  GRADE (www.gradeworkinggroup.org)

- Adaptations to GRADE for immunization PP
WHO Position on Hepatitis B Vaccine, WER, 2004

- "Following the primary vaccination schedule, almost all children are protected, probably for life, without the need for booster injections."

- However, "data on the duration of immunity, while substantial, remains incomplete"
RCT: Gambia Hepatitis Intervention Study


- 15 year follow-up
  - Nested RCT: anti-HBs response to HepB boost
  - 492 fully vaccinated as infants, born 1988-1989, identified and matched with original GHIS database

- VE (95% CI) 67.0 (58.2–74.6) against anti-HBc and 96.6 (91.5–100) against HBsAg.
GHIS Analysis (cont.)

- VE against carriage remained high at 15 years of age, similar to previous study at 9 years of age (94% and 97% respectively)

- VE against any infection declined from 82% at 9 years of age to 67% at 15 years of age

- More than 2/3rds of 15 year olds did not have detectable anti-HBs levels, similar to previous observations at 9 years of age
Observational Data

- Review in 2005 by Fitzsimons et al cited 26 studies demonstrating protection 4-15 years following primary vaccination with HepB vaccine.

- Eleven additional studies identified evidence of protection as long as 22 years post-vaccination published since 2005-2008 (English literature).

- Total of 37 observational trials using both PDV and RV demonstrated consistent results in regard to long-term protection against infection.
# Observational Studies

<table>
<thead>
<tr>
<th>Country/region (group/vaccine)</th>
<th>Years of follow-up</th>
<th>$n$</th>
<th>$[\text{Anti-HBs}] \geq 10 \text{ mIU/ml}\ (%)$</th>
<th>$\text{Anti-HBe positive}\ (%)$</th>
<th>$\text{HBsAg Positive}\ (%)$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Micronesia (infants)</td>
<td>15</td>
<td>105</td>
<td>40</td>
<td>7.6</td>
<td>0</td>
</tr>
<tr>
<td>Alaska (infants)</td>
<td>15</td>
<td>37</td>
<td>5</td>
<td>0</td>
<td>na</td>
</tr>
<tr>
<td>Gambia (infants)</td>
<td>15</td>
<td>1099</td>
<td>$13.8^1$</td>
<td>10.1</td>
<td>0.7</td>
</tr>
<tr>
<td>Saudi Arabia (infants)</td>
<td>16-18</td>
<td>1355</td>
<td>38</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Taiwan (infants)</td>
<td>20</td>
<td>843</td>
<td>33.6</td>
<td>2.7</td>
<td>1.4</td>
</tr>
<tr>
<td>Hong Kong (infants)</td>
<td>22</td>
<td>318</td>
<td>$76.5/52.4$</td>
<td>?</td>
<td>0</td>
</tr>
</tbody>
</table>
Immunological Basis for Long-term Protection

- Rapid waning anti-HBs following primary immunization
- Half of responders have anti-HBs loss in 5-15 years
- Immune memory persists during long time (despite anti-HBs)
- Immune memory demonstrated among vaccine responders as long as 23 years
Immunological Basis for Long-term Protection (cont.)

- 67% to 76% of vaccine responders demonstrated anamnestic response following booster dose

- Given long incubation of HBV, stimulation of memory cells should trigger sufficient antibody to prevent clinical consequences of HBV infection

- Very few cases of chronic HBV infections in vaccinated cohorts documented

- No clinical HBV disease observed 15-20 years post vaccination
## Evidence for Long-term Protection

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Design</th>
<th>Limitations</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>hepatitis B infection (follow-up mean 15 years; anti-HBc)</td>
<td>1 randomized trials</td>
<td>no serious limitations</td>
<td>no serious inconsistency</td>
<td>no serious indirectness²</td>
<td>no serious imprecision</td>
<td>++ + ++ +</td>
<td>CRITICAL</td>
</tr>
<tr>
<td>chronic hepatitis B infection (follow-up mean 15 years; HBsAg)</td>
<td>1 randomized trials</td>
<td>no serious limitations</td>
<td>no serious inconsistency</td>
<td>no serious indirectness²</td>
<td>no serious imprecision</td>
<td>++ + ++</td>
<td>CRITICAL</td>
</tr>
<tr>
<td>hepatitis B infection and chronic infection (various follow-up; anti-HBc and HBsAg)</td>
<td>34 observational study</td>
<td>no serious limitations</td>
<td>no serious inconsistency</td>
<td>no serious indirectness</td>
<td>no serious imprecision</td>
<td>++ ++ ++</td>
<td>CRITICAL</td>
</tr>
</tbody>
</table>
Evidence for Long-term Protection

Should primary hepatitis B series be used for long-term protection against hepatitis B virus infection?

Evidence for LT protection of HepB by outcome:

- High quality evidence to support effectiveness of a primary series of HepB to prevent any HBV infection at 15 years post vaccination of infants.
- High quality evidence to support effectiveness of a primary series of HepB to prevent chronic HBV infection at 15 years post vaccination of infants.
- Low quality evidence to support effectiveness of a primary series of HepB to prevent HBV infection at up to 22 years post-vaccination of infants.
Cautionary Note

In several recent observational trials of individuals vaccinated at birth, the response (anti-HBs) to booster HepB at 13-15 years of age, was ~50%

- Micronesia (Bialek, PIDS 2008) – n=105
- Alaska (Hammett, Vaccine 2007) – n=37
WHO Position on Hepatitis B Vaccine, WER, 2009

- HBsAg-carrier status or clinical HBV-disease rarely occurs among successfully vaccinated individuals even when the anti-HBs concentrations decline to ≤10 mIU/ml over time.

- Even absent anamnestic response following booster may not signify susceptibility to HBV in such individuals.

- HepB highly efficacious in reducing the HBsAg positivity rate 15–18 yrs after a 4-dose infant HepB (Taiwan), despite 63% vaccinees with no anti-HBs; and anti-HBs undetectable in 29% after booster dose.
WHO Position on Hepatitis B Vaccine, WER, 2009

- RCT (Gambia) showed infant vaccination provided 15 years protection against HBsAg carriage.

- Observational studies show effectiveness of HepB in preventing infection up to 22 years post-vaccination of infants.

- Although knowledge about duration of protection of HepB incomplete, including knowledge on potential role of natural boosting, no compelling evidence for recommending HepB booster dose in routine immunization programmes.
Thanks
2009 WHO Position Statement I

- All regions/associated counties should develop goals for HBV control appropriate to their epidemiologic situations.

- Control goals essential for regions and countries with intermediate/high endemicity of HBV infection or significant subpopulations with these levels of infection.

- Serologic surveys of HBsAg serve as primary tool to measure impact of immunization and achievement of the control goals supplemented by acute disease surveillance and mortality data.
In all regions of the world, all infants should receive the first dose of HepB as soon as possible (<24 hours) after birth. This should be followed by two or three doses to complete the series.

Immunization programmes should work with maternal and child health programmes to promote the administration of HepB birth dose (HepB_BD).

Timely delivery of HepB birth dose (<24 hours) should be performance measure for all immunization programs.